# persona_off · bixbench · bix-5-q4

[All trial-1 traces](../../README.md)

- Trial: **1**; endpoint: **repaired**; attempt: **2**.
- Native status: **missing_submission**; normalized native score: **0/100**.
- Recorded protocol: `researcher-review-v2`.
- Actor, simulator, and judge: **GPT-6 Astra, low reasoning**.
- Scope: chronological shared messages and handoff fields. Private tool logs, system prompts, evaluator references, and raw API requests are not included.
- A repaired endpoint belongs to the same trial; it is not an independent repeat. Zero scores and missing scientific submissions are retained.

## Shared conversation

### Event 1 — Simulator

**Message**

````text
Inspect the supplied files and any repository analysis instructions only; do not run the full analysis yet. Report count-table structure, sample identifiers and their alignment with metadata, condition and sex levels and sample counts, gene identifier mappings, and any supplied enrichment resources or specified methods. Propose an executable approach to identify the most enriched process in ASXL1-mutated versus control fibroblasts, including sex adjustment, expression filtering, differential expression, enrichment background, multiple-testing correction, and how enrichment direction and the top process will be defined. Identify consequential assumptions or uncertainties, including confounding and availability of pathway annotations. Distinguish supplied requirements from proposed choices.
````

**Interaction**

````text
initial_request
````

**Phase**

````text
initial_inspection
````

**Action**

````text
continue
````

**Approve Approach**

````text
false
````

**Evidence**

````text
Inputs include a featureCounts gene table, GENCODE and HGNC annotations, and a metadata workbook whose reported columns are sample, condition, and sex. Sample contents, applicable repository methods, and enrichment resources have not yet been inspected.
````

**Objectives Open**

````text
[
  "Inspect input schemas, sample alignment, study design, and repository requirements.",
  "Agree on differential-expression and process-enrichment methods before execution.",
  "Execute the agreed analysis and retain a notebook or script, then provide a concise answer identifying the most enriched process."
]
````

### Event 8 — Actor

**Answer**

````text
Inspection only is complete; no differential-expression or enrichment analysis has been run.

**Supplied requirements versus choices**
The public question is “Which is the most enriched process in the ASXL1-mutated fibroblasts?” The researcher explicitly requests sex adjustment and an executable plan covering filtering, differential expression, background, direction, and multiple testing. No repository analysis instructions, prescribed DE/enrichment algorithm, pathway library, or numerical thresholds were supplied: the workspace contains task.json and the four listed inputs only. Methods below are proposed choices, not methods found in the capsule.

**Observed input structure and sample alignment**
- The whitespace-delimited count table contains 60,662 unique versioned Ensembl gene IDs and 16 sample columns (60,662 × 17 including Geneid). Counts are nonnegative integers with no missing entries; 16,944 rows are zero across all 16 columns. Stripping Ensembl versions introduces no duplicate gene IDs.
- The Excel workbook has one sheet, Sheet1, with 14 rows and columns sample, condition, sex. All 14 samples occur in the count matrix in the same order. Two additional count columns, MGD1640F and MGD1641F, have no supplied metadata.
- disease/F (6): MGD1547F, MGD1550F, MGD1557F, MGD1560F, MGD1613F, MGD1616F.
- disease/M (1): MGD1544F.
- control/F (4): MGD1548F, MGD1551F, MGD1558F, MGD1615F.
- control/M (3): MGD1546F, MGD1549F, MGD1614F.
Thus the annotated comparison is seven disease versus seven control samples, with ten females and four males. I propose using these 14 and excluding the two unannotated columns, without inferring their status from identifiers.

**Gene mappings and enrichment resources**
- GENCODE v31 is 60,662 × 27 and exactly matches every count-table gene ID. It provides gene_name, gene_type, hgnc_id, genomic coordinates, and related annotation fields. There are 59,087 distinct gene names, so symbols are not unique gene identifiers. HGNC IDs are nonmissing for 37,600 rows. The apparent ont field is entirely missing; it is not a usable enrichment resource.
- The HGNC table is 46,579 × 11: 42,047 Approved, 3,334 Symbol Withdrawn, and 1,198 Entry Withdrawn entries. It supplies approved symbols, previous symbols/synonyms, HGNC IDs, and unversioned Ensembl IDs. Among Approved records, 37,513 have an Ensembl ID, including three duplicate IDs; 37,510 count genes match Approved Ensembl IDs directly. GENCODE HGNC IDs match Approved HGNC records for 37,597 genes.
- No GO, Reactome, KEGG, or other gene-set memberships are supplied. External annotation acquisition is required before any process can be identified.
- This runner currently has Python/scipy/statsmodels, but no Rscript, PyDESeq2, or gseapy. Installing Python analysis packages and obtaining a versioned annotation resource are execution dependencies, not yet demonstrated.

**Proposed executable approach (subject to approval)**
1. Write and execute a reproducible Python analysis script, saving package versions, mapping diagnostics, model diagnostics, and result tables. Read the supplied files, select/reorder the 14 annotated samples by ID, and retain unique Ensembl IDs for modelling. Interpret disease as ASXL1-mutated and control as the reference.
2. Before modelling, retain genes with at least 10 counts in at least seven of the 14 selected samples. This is a proposed fixed expression filter, applied without reference to significance. Examine library totals, normalized-count PCA, and sample distances; flag outliers rather than silently discarding them.
3. Install/use PyDESeq2 for a negative-binomial DESeq2-style model with median-ratio size factors, dispersion estimation, and design ~ sex + condition. Estimate disease minus control; positive log2 fold change means higher expression in mutant fibroblasts. Apply Benjamini–Hochberg correction to gene-level tests and define DE genes as adjusted P < 0.05, without an additional fold-change threshold. Save effect sizes, standard errors, Wald statistics, P values, and adjusted P values. Report genes excluded by outlier/independent-filtering procedures.
4. Acquire and cache a documented release of human GO Biological Process memberships (proposed library: MSigDB C5 GO:BP GMT), with source, release, and checksum. Use supplied GENCODE/HGNC links to resolve approved symbols; do not match ambiguous synonyms indiscriminately. Resolve ambiguous one-to-many mappings conservatively and deduplicate memberships. For symbol-level enrichment, choose a representative Ensembl gene per repeated approved symbol by highest overall normalized mean expression, independent of its condition effect. Report mapping losses.
5. Primary analysis: one-sided Fisher/hypergeometric overrepresentation tests separately for upregulated and downregulated DE genes. The background is the mapped, expression-filtered, statistically eligible tested genes with GO:BP annotation—not the entire genome. Test GO:BP terms containing 15–500 background genes (proposed bounds), including terms with zero selected overlap. Apply BH jointly to all tested term-by-direction hypotheses.
6. Define “most enriched in ASXL1-mutated fibroblasts” operationally as the upregulated GO:BP term with the smallest BH-adjusted P value (then raw P, then fold enrichment, then GO ID for ties), requiring enrichment FDR < 0.05. Report its term name/ID, adjusted P, overlap, and fold enrichment. This distinguishes evidence strength from simply choosing the largest fold enrichment. Downregulated enrichment will be reported separately and not called activation in mutants. If no upregulated term passes FDR, say so rather than force a winner.
7. As a sensitivity check, perform preranked GO:BP GSEA on signed disease-versus-control Wald statistics using the same documented memberships and deterministic seed; positive NES denotes mutant-associated enrichment. Report whether it supports the primary process, without switching the prespecified primary ranking after inspecting results.

**Consequential assumptions and uncertainties**
- Disease is assumed to denote ASXL1 mutation; the workbook provides no genotype details. Samples are assumed to be independent biological replicates; no donor, pairing, passage, batch, age, or mutation subtype information is supplied.
- Sex and condition are imbalanced but not completely confounded: all four sex-by-condition cells exist, so the additive design is identifiable. Only one male disease sample limits precision and robustness; a sex-by-condition interaction is not a reliable primary target here. Unknown batch/donor confounding cannot be adjusted away from these inputs.
- The two unannotated samples cannot safely enter the model without additional metadata. Their exclusion is consequential but preferable to inventing labels.
- “Most enriched” does not specify ontology, ORA versus GSEA, statistical strength versus fold enrichment, or direction. The explicit operational definition above is proposed rather than supplied; annotation release and redundant GO terms can change the exact top label.
- External resource/network/package availability is unverified. If the proposed library cannot be obtained, I will report the dependency issue rather than invent memberships or silently substitute a different process database.

Please approve this plan or specify changes before main analysis begins.
````

**Stage**

````text
plan
````

**Evidence**

````text
File inspection found only task.json and four data inputs. Count matrix: 60,662 genes × 16 samples, no missing/negative/noninteger values, 16,944 all-zero rows. Metadata: 14 samples, control F=4/M=3 and disease F=6/M=1; MGD1640F and MGD1641F lack metadata. All 60,662 gene IDs match GENCODE exactly. GENCODE ont has zero nonmissing values; no supplied pathway resource. Rscript, pydeseq2, and gseapy absent; scipy and statsmodels present.
````

**Assumptions**

````text
[
  "Disease denotes ASXL1-mutated fibroblasts.",
  "The 14 annotated samples are independent biological replicates.",
  "Exclude MGD1640F and MGD1641F unless metadata becomes available.",
  "GO Biological Process upregulated overrepresentation is the proposed primary interpretation of enrichment."
]
````

**Uncertainties**

````text
[
  "Unrecorded donor or batch confounding cannot be assessed from supplied metadata.",
  "Sex adjustment is estimable but male disease representation is only one sample.",
  "Annotation resource acquisition and Python dependency installation remain unverified.",
  "No supplied method fixes ontology, enrichment algorithm, thresholds, or direction."
]
````

### Event 9 — Simulator

**Message**

````text
Proceed with the proposed analysis. I approve using the 14 annotated samples, excluding the two without metadata, the sex-adjusted disease-versus-control model, and the stated filtering, mapping, GO:BP enrichment, multiplicity correction, and sensitivity analysis. Treat disease-as-ASXL1-mutated and independent replication as assumptions, not verified facts. Preserve the prespecified upregulated ORA ranking, but report the leading downregulated and positive/negative GSEA results as context so the question's directional ambiguity remains transparent. Document the exact annotation release and acquisition source; if dependencies or memberships cannot be obtained, report the concrete blocker rather than silently changing methods. Execute and retain the reproducible script and result tables. Return the leading process with quantitative enrichment evidence, sample/model and mapping diagnostics, and any important disagreement between ORA and GSEA. The final candidate should include a concise answer, payload.executed_analysis set true only after execution, and artifacts.analysis pointing to the executed script or notebook.
````

**Interaction**

````text
next_task
````

**Phase**

````text
approach_review
````

**Action**

````text
continue
````

**Approve Approach**

````text
true
````

**Evidence**

````text
Inspection reports complete matching GENCODE IDs, 14 metadata-aligned samples with both conditions represented in each sex, and two unannotated columns. No pathway memberships or mandated algorithm were found. The proposed approach addresses sex imbalance and explicitly defines enrichment while acknowledging unresolved annotation access and biological assumptions; it is suitable to execute.
````

**Objectives Open**

````text
[
  "Execute the sex-adjusted differential-expression and GO:BP enrichment analysis.",
  "Identify the top mutant-associated process and assess directional and GSEA context.",
  "Report quantitative evidence and retain an executed analysis artifact in the submission contract."
]
````

### Event 18 — Actor

**Answer**

````text
The most enriched process cannot yet be determined: the approved differential-expression and enrichment workflow is blocked by unavailable dependencies and GO memberships. No process ranking or enrichment statistics have been fabricated.

Executed input/filter/model diagnostics are retained in analysis.py and results/. Of 60,662 genes, 17,883 pass the approved filter (at least 10 counts in at least seven annotated samples). Among these, 15,334 map through GENCODE HGNC IDs to approved HGNC symbols, representing 15,329 distinct symbols; these are preliminary mapping counts, not the final enrichment background. The 14-sample additive model matrix has rank 3 of 3 and 11 residual degrees of freedom. Sex counts remain disease F=6/M=1 and control F=4/M=3. The two samples without metadata were excluded. Disease-as-ASXL1-mutated and independent replication remain assumptions.

Concrete blockers:
- PyDESeq2 and gseapy are absent. An isolated-environment pip installation attempt failed with temporary DNS resolution failure when accessing the package index. The initial system pip attempt was also rejected by the externally managed environment restriction.
- The intended annotation is MSigDB release 2025.1.Hs, C5 GO Biological Process, from https://data.broadinstitute.org/gsea-msigdb/msigdb/release/2025.1.Hs/c5.go.bp.v2025.1.Hs.symbols.gmt. Both curl and the executed script's urllib acquisition failed to resolve the host. No annotation file was obtained, so no checksum or verified membership counts can be reported. This is the intended release, not a successfully acquired resource.
- The supplied files contain no alternative pathway memberships. No method or library was silently substituted.

Consequently DE, up/down ORA, and positive/negative GSEA have not run; agreement, the leading process, adjusted P values, and enrichment direction cannot be evaluated. The retained script is an executed diagnostics/preflight script, not a completed DE/enrichment implementation. Restoring package/resource access or supplying the approved packages and GMT locally is required to continue. The payload conservatively leaves executed_analysis=false because the requested substantive analysis has not executed.
````

**Stage**

````text
result
````

**Evidence**

````text
Executed python analysis.py: 17,883 genes pass filter; 15,334 filtered genes have approved symbols, 15,329 unique symbols; model rank=3/3 and residual df=11. results/execution_report.json records missing pydeseq2 and gseapy and annotation download URLError(gaierror(-3, 'Temporary failure in name resolution')). Script stops explicitly before DE/enrichment.
````

**Assumptions**

````text
[
  "Disease denotes ASXL1-mutated fibroblasts; not genotype-verified.",
  "Samples represent independent biological replicates; not donor-verified."
]
````

**Uncertainties**

````text
[
  "The leading enriched process remains unknown.",
  "Network access or locally supplied approved dependencies and gene memberships are needed.",
  "Unrecorded batch/donor confounding remains unassessable; sex is imbalanced but the additive design is full rank."
]
````

### Event 19 — Simulator

**Message**

````text
Conclude with a concise blocked final answer: the most enriched process could not be determined because differential expression and enrichment were not executed; required packages and GO memberships could not be acquired owing to DNS failures. Do not interpret this as absence of biological enrichment. Retain payload.executed_analysis=false and artifacts.analysis="analysis.py", explicitly identifying that artifact as the executed diagnostics/preflight script rather than completed enrichment analysis.
````

**Interaction**

````text
conclude
````

**Phase**

````text
result_review
````

**Action**

````text
stop
````

**Approve Approach**

````text
false
````

**Evidence**

````text
Reported execution establishes input filtering and an identifiable sex-adjusted design, but no DE or enrichment results. Package installation and GO membership acquisition both failed with DNS errors, and no supplied memberships are available. The agent respected the agreed requirement to report a concrete dependency blocker rather than substitute methods or fabricate results; further analysis cannot be supported by the currently available resources.
````

**Objectives Open**

````text
[
  "Identify the most enriched process after required analysis packages and GO memberships become available and the substantive workflow is executed."
]
````

### Event 20 — Controller termination

**Reason**

````text
No complete, researcher-reviewed final candidate at termination
````

## Provenance

````text
{
  "source_run": "runs/openai-astra-top2-first-pass",
  "repair_run": "runs/repair-1-openai-astra-top2-first-pass",
  "event_log": "runs/repair-1-openai-astra-top2-first-pass/episodes/bixbench_bix-5-q4-971a49465bcf/persona_off/attempt-2/output/bixbench_bix-5-q4-971a49465bcf/controller/events.jsonl",
  "event_log_sha256": "496396799d929055ad26b0c5e315cfae837cec9824e42c76c6f39d10f5a91956",
  "models": {
    "actor": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "researcher": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "judge": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    }
  }
}
````
